Cannabinoid Hyperemesis Syndrome. Prospective Multicenter Study of Patients Admitted to Adult Emergency Departments in Maine-et-Loire.

Cannabinoid hyperemesis syndrome (CHS) is characterized by incoercible abdominal pain and vomiting in patients with chronic cannabis use. Patients are relieved by hot showers, an easily performed diag...

Lead sponsor: University Hospital, Angers•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Julien DENIS, Doctor

CONTACT

+33 2 41 53 30 30 julien.denis@ch-saumur.fr

Trial snapshot

StatusRECRUITING

Phase—

Enrollment3,000

Start dateJul 2025

Last updatedAug 28, 2025

Condition

D000096704 Cannabinoid Hyperemesis Syndrome

Locations shown

Angers Centre Hospitalier Universitaire (CHU)

Angers

Centre Hospitalier de Cholet

Cholet

Centre Hospitalier de Saumur

Saumur

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 28, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions